FDA Warns Compounders About Injectable Glutathione: What Pharmacy Owners Should Take Away From It

On August 27, 2026, the U.S. Food and Drug Administration issued a new warning to pharmacies and other compounders after receiving reports of adverse events involving at least 30 patients who received compounded intravenous glutathione.

According to the FDA, the glutathione involved was compounded by multiple pharmacies. But those pharmacies had something important in common: they had obtained glutathione from the same supplier and from the same lot.

The ingredient was labeled as dietary supplement grade.

According to the FDA, that grade of ingredient is not appropriate for use in making injectable drugs.

Two pharmacies in Texas have conducted recalls involving compounded glutathione injections after elevated endotoxin levels were identified. Reported patient reactions have included fever, chills, nausea, vomiting, pain, dizziness, changes in blood pressure and symptoms consistent with serious systemic reactions.

For pharmacy owners, particularly those involved in sterile compounding, there is an important lesson here that goes beyond this particular product.

Your pharmacy's risk doesn't begin when a prescription reaches the counter. It can begin much earlier in the supply chain.

Knowing Your Supplier Is Part of Managing Your Risk

One of the most important parts of the FDA's warning isn't simply that patients experienced adverse events.

It's what the FDA is telling compounders to do about it.

The agency is reminding pharmacies to know where their active pharmaceutical ingredients and excipients are coming from and to ensure those ingredients are manufactured and tested to standards appropriate for their intended use.

That's an important distinction.

A pharmacy can have excellent pharmacists, detailed procedures and strong internal controls, but those controls don't eliminate the risks created by the ingredients entering the pharmacy.

For a compounding pharmacy, supplier selection isn't simply a purchasing decision.

It's a patient-safety decision and a risk-management decision.

Pharmacy owners should be asking questions such as:

• Where are our ingredients coming from?
• How are our suppliers evaluated?
• What documentation do we maintain regarding the ingredients we purchase?
• Are those ingredients appropriate for the route of administration for which we're using them?
• Who is responsible for verifying that information?
• If a supplier or ingredient is later associated with a problem, how quickly can we identify the preparations and patients potentially affected?

Those questions matter before an incident ever occurs.

Testing Alone Isn't the Entire Answer

Another point from the FDA's warning deserves attention.

The agency cautions compounders against relying solely on finished-product testing as a way to ensure quality. Instead, the FDA emphasizes building quality throughout the compounding process.

That's an important risk-management principle far beyond this particular incident.

The safest process isn't necessarily the one that catches every mistake at the end.

It's the one designed to prevent as many mistakes as possible from reaching the end in the first place.

That can include supplier qualification, ingredient verification, documentation, pharmacist checks, preparation procedures, environmental controls, employee training and the ability to trace ingredients and preparations when something goes wrong.

None of those systems guarantees that an error will never occur.

But strong systems can reduce both the likelihood of an event and the potential severity when one does occur.

What Happens When One Ingredient Affects Multiple Patients?

This FDA alert also illustrates something particularly important from an insurance perspective.

The FDA isn't describing a problem involving one prescription and one patient.

At least 30 patients reportedly experienced adverse events after receiving IV glutathione, and multiple compounding pharmacies were involved.

For an individual pharmacy, imagine discovering that an ingredient used in several compounded preparations may be contaminated or otherwise inappropriate.

Now the issue potentially extends beyond one patient.

You may need to identify every preparation made using that ingredient or lot.

You may need to determine which patients received those preparations.

You may need to notify prescribers or patients.

There could be a recall.

There could be regulatory scrutiny.

And if patients were injured, there could potentially be multiple professional liability claims.

This is where pharmacy risk management and pharmacy insurance begin to overlap.

Would Your Professional Liability Coverage Respond the Way You Expect?

Most pharmacy owners know whether they carry professional liability insurance.

Far fewer have probably sat down and considered how that policy would respond if one underlying problem affected several patients.

That's worth understanding.

Depending on the policy, there may be a per-claim limit as well as an aggregate limit. The policy may also contain language addressing claims arising from related acts, common causes or similar circumstances.

Those details can become extremely important when multiple patients are involved.

The question isn't simply:

“Do we have professional liability insurance?”

A better question is:

“If one compounding event resulted in several serious patient claims, how would our particular policy respond?”

That's a conversation worth having with your insurance professional before the answer matters.

The Insurance Company Needs to Understand What Your Pharmacy Actually Does

There's another important lesson here for pharmacies involved in compounding.

Your professional liability carrier should have an accurate picture of your operations.

A traditional retail pharmacy dispensing commercially manufactured medications presents a different risk profile than a pharmacy performing sterile compounding and preparing injectable medications.

That doesn't mean compounding is inherently uninsurable or that pharmacies shouldn't provide these services.

It means the insurance program should reflect the actual operation.

If your pharmacy has expanded into sterile compounding, added new types of preparations, substantially increased compounding volume or otherwise changed its services, those changes should be discussed with your insurance professional.

Your coverage should be built around the pharmacy you're operating today, not simply the pharmacy that existed when the policy was originally purchased.

Don't Forget the Regulatory Side

Patient injury isn't the only potential consequence of a significant compounding event.

A serious incident can also attract attention from regulators and potentially result in investigations or proceedings involving the pharmacy or individual pharmacists.

That's why I believe license-defense coverage deserves much more attention than it often receives.

For an individual pharmacist, your professional license is your livelihood.

For the pharmacy owner, the pharmacy's permit or license is fundamental to the business.

Those are different exposures from the damages alleged in a professional liability lawsuit.

When reviewing pharmacy coverage, owners and pharmacists should understand what protection is available for regulatory or licensing proceedings, what the applicable limits are, and whether the protection applies appropriately to both the business and the professionals working within it.

Insurance Can't Replace Good Risk Management

It's tempting for an insurance professional to look at an event like this entirely through the lens of coverage.

I don't think that's the right lesson.

Insurance comes into play after something has gone wrong.

The better outcome is preventing the loss in the first place.

That's why the most important takeaway from the FDA's latest warning may have very little to do with insurance:

Know what's entering your pharmacy. Know where it came from. Know how it's being used. And make sure your procedures allow you to trace it quickly if a problem develops.

Insurance is there for the day those controls aren't enough.

Good risk management is about doing everything reasonably possible to keep that day from happening.

A Good Time to Ask Better Questions

The FDA's August 27 warning is specific to compounded injectable glutathione, but the questions it raises are much broader.

For pharmacy owners involved in compounding, this is a good opportunity to review both operational procedures and insurance coverage.

Ask yourself:

Do we know and properly evaluate our suppliers?

Can we quickly trace ingredients from receipt through preparation to the patient?

Does our insurance carrier fully understand our compounding operations?

Do we understand our professional liability limits if multiple patients are involved?

Do our pharmacists have meaningful license-defense protection?

Have our operations changed since our insurance program was last thoroughly reviewed?

You don't need to wait for a claim, recall or regulatory investigation to answer those questions.

In fact, that's probably the worst possible time to start asking them.

---

A Resource for Pharmacy Owners

I work with independent pharmacies on professional liability, business insurance and risk-management issues.

If your pharmacy compounds medications, or your operations have changed since your insurance program was originally put in place, I'm always happy to help you take a second look at how your current coverage addresses those exposures.

The goal isn't to assume something is wrong with your current insurance.

It's to make sure you understand what you have before you need it.

Jeremy A. Jones Insurance and Risk Management for Healthcare Professionals

For a broader look at the coverage considerations for your practice, visit the pharmacy insurance page.